Catalent to buy cell and gene therapy CDMO MaSTherCell for $315m

This article was originally published here

Established in 2011, MaSTherCell Global is a technology-focused cell and gene therapy contract development and manufacturing organisation (CDMO) that serves cell therapy innovators. Catalent chair and CEO John

The post Catalent to buy cell and gene therapy CDMO MaSTherCell for $315m appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply